Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai Eyes New Product Launches, Strong Growth In Asia To Offset Aricept Patent Loss

This article was originally published in PharmAsia News

Executive Summary

Preparing for patent expiry for blockbuster Alzheimer's disease drug Aricept (donepezil) in November, Eisai will step up efforts to launch new products in the fiscal year, company President Haruo Naito said during the company's Feb. 2 earnings conference call

You may also be interested in...

Eisai Opens Fourth Knowledge Center In India As Launch Pad For Next-generation Global Products; Focus On Affordability

Sitting on a 50-acre campus at Southern India's Jawaharlal Nehru Pharma City, Eisai's newly minted Knowledge Center India is the company's first integrated facility that includes API production and research functions in one site, bringing the company one step further toward creating a global supply and research hub

Eisai Draws U.S. FDA Warning Letter For Misleading Efficacy and Safety Claims

WASHINGTON - U.S. FDA issued a warning letter to Eisai for "serious" violations regarding a Dacogen (decitabine) marketing document that minimize risk and "greatly overstates the efficacy of Dacogen.

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts